Search Share Prices
Verona Pharma's share prices climb almost 20% after trial results
Verona Pharma's shares leapt after it announced on Friday that it had obtained "favourable" top line data from its most recent clinical trials for a treatment of cystic fibrosis (CF).
According to data from the clinical stage biopharmaceutical company's phase 2a trial, Nebulized RP554 has a positive pharmacokinetic (PK) and pharmacodynamic (PD) profile and was seen to achieve "statistically significant (P